Literature DB >> 17846719

Effect of loxapine on electrical brain activity, intracranial pressure, and middle cerebral artery flow velocity in traumatic brain-injured patients.

Thomas Lescot1, Ana Rosa Pereira, Lamine Abdennour, Paola Sanchez-Pena, Lionel Naccache, Pierre Coriat, Louis Puybasset.   

Abstract

INTRODUCTION: Delirium is a frequent complication of traumatic brain injury, especially during the weaning period. Antipsychotic drugs are often used in this case. Loxapine is a tricyclic antipsychotic drug with sedating properties. The effects of intravenous loxapine on EEG as well as on systemic and cerebral hemodynamics after traumatic brain injury are unknown.
METHODS: Seven sedated and mechanically ventilated traumatic brain injured patients were studied 11 +/- 5 days after trauma. They were on continuous perfusion of sufentanil and midazolam. Left and right spectral edge frequency (SEFl, SEFr) of continuous EEG recording, intracranial pressure (ICP), mean flow velocity of the middle cerebral artery (MFV(MCA)) and mean arterial pressure (MAP) were simultaneously recorded and digitalized before and after loxapine infusion (10 mg in 10 min of continuous infusion).
RESULTS: Loxapine induced no significant change on MAP, MFV. On the contrary, it decreased ICP and both SEFl, SEFr. ETCO(2 )and the dose of vasopressors were not altered during the study period.
CONCLUSION: 10 mg of loxapine administered intravenously over 10 min decreased brain electrical activity. There is a concomitant reduction in ICP without any significant change in cerebral blood flow velocity. The use of intravenous loxapine to control agitation is not accompanied by deleterious hemodynamic or systemic effects in ICU's traumatic brain injured patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17846719     DOI: 10.1007/s12028-007-0051-7

Source DB:  PubMed          Journal:  Neurocrit Care        ISSN: 1541-6933            Impact factor:   3.210


  14 in total

Review 1.  The use of atypical antipsychotics in traumatic brain injury.

Authors:  Elie Paul Elovic; Ramon Lansang; Yali Li; Joseph H Ricker
Journal:  J Head Trauma Rehabil       Date:  2003 Mar-Apr       Impact factor: 2.710

2.  EEG Global Field Power spectrum changes after a single dose of atypical antipsychotics in healthy volunteers.

Authors:  Keizo Yamada; Toshiaki Isotani; Satoshi Irisawa; Masafumi Yoshimura; Aran Tajika; Takami Yagyu; Akemi Saito; Toshihiko Kinoshita
Journal:  Brain Topogr       Date:  2004       Impact factor: 3.020

Review 3.  Agitation after traumatic brain injury: considerations and treatment options.

Authors:  Lisa A Lombard; Ross D Zafonte
Journal:  Am J Phys Med Rehabil       Date:  2005-10       Impact factor: 2.159

4.  A quantitative computed tomography assessment of brain weight, volume, and specific gravity in severe head trauma.

Authors:  Thomas Lescot; Marie-Pierre Bonnet; Abederrezak Zouaoui; Jean-Charles Muller; Catalin Fetita; Pierre Coriat; Louis Puybasset
Journal:  Intensive Care Med       Date:  2005-07-01       Impact factor: 17.440

5.  EEG abnormalities during treatment with typical and atypical antipsychotics.

Authors:  Franca Centorrino; Bruce H Price; Margaret Tuttle; Won-Myong Bahk; John Hennen; Matthew J Albert; Ross J Baldessarini
Journal:  Am J Psychiatry       Date:  2002-01       Impact factor: 18.112

6.  Haloperidol use is associated with lower hospital mortality in mechanically ventilated patients.

Authors:  Eric B Milbrandt; Alexander Kersten; Lan Kong; Lisa A Weissfeld; Gilles Clermont; Mitchell P Fink; Derek C Angus
Journal:  Crit Care Med       Date:  2005-01       Impact factor: 7.598

7.  Delirium as a predictor of mortality in mechanically ventilated patients in the intensive care unit.

Authors:  E Wesley Ely; Ayumi Shintani; Brenda Truman; Theodore Speroff; Sharon M Gordon; Frank E Harrell; Sharon K Inouye; Gordon R Bernard; Robert S Dittus
Journal:  JAMA       Date:  2004-04-14       Impact factor: 56.272

8.  The effect of droperidol on objective markers of patient cooperation and vital signs during esophagogastroduodenoscopy: a randomized, double-blind, placebo-controlled, prospective investigation.

Authors:  J S Barthel; J B Marshall; P D King; S A Afridi; L G Gibb; R Madsen
Journal:  Gastrointest Endosc       Date:  1995-07       Impact factor: 9.427

9.  5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation.

Authors:  S Kapur; R B Zipursky; G Remington; C Jones; J DaSilva; A A Wilson; S Houle
Journal:  Am J Psychiatry       Date:  1998-07       Impact factor: 18.112

10.  Loxapine versus olanzapine in the treatment of delirium following traumatic brain injury.

Authors:  Deborah Krieger; Keith Hansen; Colleen McDermott; Roy Matthews; Rachel Mitchell; Natasha Bollegala; Shree Bhalerao
Journal:  NeuroRehabilitation       Date:  2003       Impact factor: 2.138

View more
  3 in total

1.  Beneficial effects of loxapine on agitation and breathing patterns during weaning from mechanical ventilation.

Authors:  Benjamin Sztrymf; Guillaume Chevrel; Fabrice Bertrand; Dimitri Margetis; Dominique Hurel; Jean-Damien Ricard; Didier Dreyfuss
Journal:  Crit Care       Date:  2010-05-12       Impact factor: 9.097

2.  Octopamine signaling in the metazoan pathogen Schistosoma mansoni: localization, small-molecule screening and opportunities for drug development.

Authors:  Nelly El-Sakkary; Steven Chen; Michelle R Arkin; Conor R Caffrey; Paula Ribeiro
Journal:  Dis Model Mech       Date:  2018-07-30       Impact factor: 5.758

Review 3.  The role of systematic reviews in pharmacovigilance planning and Clinical Trials Authorisation application: example from the SLEEPS trial.

Authors:  Carrol Gamble; Andrew Wolf; Ian Sinha; Catherine Spowart; Paula Williamson
Journal:  PLoS One       Date:  2013-03-15       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.